首页> 美国卫生研究院文献>Malaria Journal >Implementation of a reference standard and proficiency testing programme by the World Wide Antimalarial Resistance Network (WWARN)
【2h】

Implementation of a reference standard and proficiency testing programme by the World Wide Antimalarial Resistance Network (WWARN)

机译:全世界抗疟疾抵抗网络(WWARN)实施参考标准和能力验证计划

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThe Worldwide Antimalarial Resistance Network (WWARN) is a global collaboration to support the objective that anyone affected by malaria receives effective and safe drug treatment. The Pharmacology module aims to inform optimal anti-malarial drug selection. There is an urgent need to define the drug exposure - effect relationship for most anti-malarial drugs. Few anti-malarials have had their therapeutic blood concentration levels defined. One of the main challenges in assessing safety and efficacy data in relation to drug concentrations is the comparability of data generated from different laboratories. To explain differences in anti-malarial pharmacokinetics in studies with different measurement laboratories it is necessary to confirm the accuracy of the assay methods. This requires the establishment of an external quality assurance process to assure results that can be compared. This paper describes this process.
机译:背景全球抗疟抗药性网络(WWARN)是一项全球合作,旨在支持以下目标:受疟疾影响的任何人都应接受有效且安全的药物治疗。药理学模块旨在告知最佳抗疟药选择。迫切需要定义大多数抗疟疾药物的药物暴露-效应关系。很少有抗疟药定义其治疗性血液浓度水平。评估与药物浓度相关的安全性和有效性数据的主要挑战之一是来自不同实验室的数据的可比性。为了解释在不同测量实验室进行的研究中抗疟药药代动力学的差异,有必要确认测定方法的准确性。这要求建立外部质量保证流程,以确保可以比较结果。本文介绍了此过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号